Your browser doesn't support javascript.
loading
Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib.
Frankel, Arthur E; Reddy, Renuka; DeSuza, Kayla R; Deeb, Khaled; Carlin, Aaron F; Smith, Davey; Xie, Yushuang; Naik, Eknath; Silver, Richard T; Hasselbalch, Hans C.
Afiliação
  • Frankel AE; Department of Medicine West Palm Beach VA Medical Center West Palm Beach FL USA.
  • Reddy R; Department of Medicine West Palm Beach VA Medical Center West Palm Beach FL USA.
  • DeSuza KR; Department of Medicine West Palm Beach VA Medical Center West Palm Beach FL USA.
  • Deeb K; Department of Medicine West Palm Beach VA Medical Center West Palm Beach FL USA.
  • Carlin AF; Division of Infectious Disease UCSD Medical School San Diego CA USA.
  • Smith D; Division of Infectious Disease UCSD Medical School San Diego CA USA.
  • Xie Y; Department of Medicine West Palm Beach VA Medical Center West Palm Beach FL USA.
  • Naik E; Department of Medicine West Palm Beach VA Medical Center West Palm Beach FL USA.
  • Silver RT; Division of Hematology and Medical Oncology Weill Cornell Medicine New York NY USA.
  • Hasselbalch HC; Department of Hematology Zealand University Hospital Roskilde Denmark.
Clin Case Rep ; 9(4): 2228-2235, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33936671
ABSTRACT
An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article